*June 2018*

**Ground breaking Raman work presented at the Cancer Research UK Brain Tumour Conference**

Renishaw has collaborated with scientists at Oxford Radcliffe Hospital to investigate the capability of Raman spectroscopy to classify gliomas, in terms of their genetic subtypes, using different pathological preparations. This work was presented at the recent Cancer Research UK Brain Tumour Conference, 2018 held in London from 1-3 May 2018.

James Livermore, a Clinical Research Training Fellow in the Nuffield Department of Clinical Neuroscience at the University of Oxford, presented a poster titled “Genetic classification of gliomas using Raman spectroscopy”. The poster was co-authored by Oxford University colleagues from the Department of Neurosurgery and Neuropathology, the Department of Chemistry, and experts from Renishaw.

The work highlighted the potential use of Raman spectroscopy for rapid, intra-operative glioma genetic classification. The genetic sub-classification of glioma tumours is essential for pathological diagnosis and prognostication. Current methods for genetic classification include immunohistochemistry with a mutation-specific antibody and targeted DNA sequencing, which take several days to complete.
In this study, Raman spectroscopy showed the potential to provide a non-invasive and non-destructive tool to probe the unique molecular vibrations of tissue samples, allowing for rapid sample analysis to aid in clinical decision making.

Renishaw’s new Biological Analyser has shown that with further research it has the future potential to aid surgeons to tailor their surgical strategy based on a patient’s specific tumour genetics.

Renishaw’s Biological Analyser enables the rapid collection of detailed information on biological samples, without the need for complex sample preparation. Find out how Renishaw’s Raman instruments can be used for biological research by visiting [www.renishaw.com/bio](http://www.renishaw.com/bio)

More information about the conference can be found at <http://www.cancerresearchuk.org/funding-for-researchers/research-events-and-conferences/brain-tumour-conference-2018>

**-ENDS-**

**About Renishaw**

Renishaw is one of the world's leading engineering and scientific technology companies, with expertise in precision measurement and healthcare. The company supplies products and services used in applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It is also a world leader in the field of additive manufacturing (also referred to as 3D printing), where it is the only UK business that designs and makes industrial machines which ‘print' parts from metal powder.

The Renishaw Group currently has more than 70 offices in 35 countries, with over 4,500 employees, of which 3,000 people are employed within the UK. The majority of the company's R&D and manufacturing is carried out in the UK and for the year ended June 2017 Renishaw achieved sales of £536.8 million of which 95% was due to exports. The company's largest markets are the China, USA, Germany and Japan.

The Company's success has been recognised with numerous international awards, including eighteen Queen's Awards recognising achievements in technology, export and innovation. Renishaw received a Queen’s Award for Enterprise 2014, in the Innovations category, for the continuous development of the inVia confocal Raman microscope. For more information visit [www.renishaw.com](http://www.renishaw.com)

### **For further information**

Please contact:

|  |  |
| --- | --- |
| David ReeceRenishaw plcNew MillsWotton-under-EdgeGloucestershire GL12 8JR UKTel: +44 1453 523968 (direct)Tel: +44 1453 524524 (switchboard)Fax: +44 1453 523901Email: david.reece@renishaw.com[www.renishaw.com/raman](http://www.renishaw.com/raman) |  |